Resource Summary Report

Generated by dkNET on Sep 19, 2026

Cyclin E1 (D7T3U)

RRID:AB_2783554
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 20808, RRID:AB_2783554

Antibody Information

URL: http://antibodyregistry.org/AB_2783554

Proper Citation: Cell Signaling Technology Cat# 20808, RRID:AB_2783554

Target Antigen: Cyclin E1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W

Antibody Name: Cyclin E1 (D7T3U)

Description: This monoclonal targets Cyclin E1

Target Organism: rat, mouse, human

Clone ID: D7T3U

Antibody ID: AB_2783554

Vendor: Cell Signaling Technology

Catalog Number: 20808

Record Creation Time: 20231110T032958+0000

Record Last Update: 20260829T083538+0000

Ratings and Alerts

No rating or validation information has been found for Cyclin E1 (D7T3U).

No alerts have been found for Cyclin E1 (D7T3U).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. Cell reports, 45(7), 117559.

Koppenhafer SL, et al. (2026) DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. Oncogene, 45(28), 2823.

Sethi SC, et al. (2025) Chromatin remodeling activity of EP400 safeguards chromosomal stability by preventing CENP-A mislocalization. Cell reports, 44(11), 116423.

Lamichhane A, et al. (2025) Targeting CAFs-Mediated Stromal Signaling in a Patient-Derived Organotypic Colorectal Tumor Model. Molecular cancer therapeutics, 24(8), 1265.

Li X, et al. (2025) SLC4A11 is a targetable marker correlated with therapeutic responses in ovarian cancer. Journal of ovarian research, 18(1), 167.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. NPJ breast cancer, 11(1), 135.

Guo Y, et al. (2025) Novel compounds with promising HuH-7 inhibitory activity as new cancer drug candidates: derivatives of N,N'-diphenylurea linked with 1,2,3-triazole. Journal of enzyme inhibition and medicinal chemistry, 40(1), 2585597.

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. Cell reports. Medicine, 6(2), 101929.

Tiburcio PDB, et al. (2025) Suppressing proteasome activity enhances sensitivity to actinomycin D in diffuse anaplastic Wilms tumor. Cell reports. Medicine, 6(5), 102133.

Goto Y, et al. (2024) A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC. Cancer research communications, 4(7), 1850.

Wang Z, et al. (2024) UA influences the progression of breast cancer via the AhR/p27Kip1/cyclin E pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 38(18), e70058.

Zwirner S, et al. (2024) First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187(7), 1666.

Tiburcio PDB, et al. (2024) Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor. bioRxiv : the preprint server for biology.

Abdelrahim M, et al. (2024) Light-mediated intracellular polymerization. Nature protocols.

Chen A, et al. (2024) PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Molecular cancer therapeutics, 23(10), 1494.

Takashima S, et al. (2024) Alternative mRNA splicing events and regulators in epidermal differentiation. Cell reports, 43(3), 113814.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience, 27(7), 109978.

Dietrich C, et al. (2024) INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. Cancer discovery, 14(3), 446.

Yang J, et al. (2024) Mecp2 fine-tunes quiescence exit by targeting nuclear receptors. eLife, 12.

M??ller L, et al. (2023) Plakophilin 3 facilitates G1/S phase transition and enhances proliferation by capturing RB protein in the cytoplasm and promoting EGFR signaling. Cell reports, 42(1), 112031.